Current recommendations for tumor surveillance in individuals carrying pathogenic DICER1 variants entail regular clinical and imaging assessments, such as chest radiography or computed tomography (CT) and ultrasound of the thyroid, abdomen, and pelvis. This evidence concerns the gene DICER1 and neoplasm.